These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 15883586

  • 1. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Gross AJ, Busse M, Leonard J, Schumacher H.
    Prostate Cancer Prostatic Dis; 2005; 8(3):210-4. PubMed ID: 15883586
    [Abstract] [Full Text] [Related]

  • 2. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR, Baert L, Thind P, Höfner K, Khoe GS, Spångberg A.
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [Abstract] [Full Text] [Related]

  • 3. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A, Hernández C, Marqués A, Prats J, Espinosa FJ.
    Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
    [Abstract] [Full Text] [Related]

  • 4. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain.
    Batista JE, Palacio A, Torrubia R, Hernández C, Vicente J, Resel L, Omnilife Group.
    Arch Esp Urol; 2002 May; 55(1):97-105. PubMed ID: 11957763
    [Abstract] [Full Text] [Related]

  • 5. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T.
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [Abstract] [Full Text] [Related]

  • 6. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC.
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I.
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [Abstract] [Full Text] [Related]

  • 8. Impact of medical treatments for benign prostatic hyperplasia on sexual function.
    Giuliano F.
    BJU Int; 2006 Apr; 97 Suppl 2():34-8; discussion 44-5. PubMed ID: 16507052
    [Abstract] [Full Text] [Related]

  • 9. The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
    Nickel JC, Elhilali M, Emberton M, Vallancien G, Alf-One Study Group.
    BJU Int; 2006 Jun; 97(6):1242-6. PubMed ID: 16686719
    [Abstract] [Full Text] [Related]

  • 10. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N, Tsukamoto T, Iwasawa A, Furuya R, Sonoda T, Mori M, Hokkaido Urological Disorders Conference Writing Group.
    Urol Int; 2009 Jun; 83(1):49-54. PubMed ID: 19641359
    [Abstract] [Full Text] [Related]

  • 11. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB, Myers JB, O'Donnell C, Crawford ED.
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [Abstract] [Full Text] [Related]

  • 12. Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea.
    Chang HS, Park CH, Kim DK, Park JK, Hong SJ, Chung BH, Lee JG, Kim CS, Lee KS, Kim JC.
    Urology; 2010 May; 75(5):1156-61. PubMed ID: 19914692
    [Abstract] [Full Text] [Related]

  • 13. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC.
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [Abstract] [Full Text] [Related]

  • 14. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A, Rosen R, Kuritzky L.
    Int J Impot Res; 2007 Nov; 19(4):386-92. PubMed ID: 17377613
    [Abstract] [Full Text] [Related]

  • 15. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H, Yokoyama E, Onodera Y, Utsunomiya T, Tokunaga M, Tojo T, Fujii N, Yanada S.
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J.
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [Abstract] [Full Text] [Related]

  • 17. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
    Schulman CC.
    Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K, Ota S, Okano T, Hamano S, Ohki T, Furuya Y, Ichikawa T.
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [Abstract] [Full Text] [Related]

  • 19. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 20. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M, Rosenberg MT, Perelman MA.
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.